{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:06:19Z","timestamp":1787061979040,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10637-025-01593-w","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:24:28Z","timestamp":1763771068000},"page":"1201-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan"],"prefix":"10.1007","volume":"43","author":[{"given":"Yasuhiro","family":"Mihashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohide","family":"Komuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tsukaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Katsurada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Takeyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiichiro","family":"Otsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tetsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shiroyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Tachihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"1593_CR1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/j.bbapap.2012.10.008","volume":"1834","author":"X Wang","year":"2013","unstructured":"Wang X (2013) Structural studies of GDNF family ligands with their receptors-insights into ligand recognition and activation of receptor tyrosine kinase RET. Biochimica et Biophysica Acta (BBA) 1834:2205\u20132212","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"18","key":"1593_CR2","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1101\/gad.205001","volume":"15","author":"E de Graaff","year":"2001","unstructured":"de Graaff E, Srinivas S, Kilkenny C et al (2001) Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev 15(18):2433\u20132444. https:\/\/doi.org\/10.1101\/gad.205001","journal-title":"Genes Dev"},{"key":"1593_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101911","volume":"81","author":"AY Li","year":"2019","unstructured":"Li AY, McCusker MG, Russo A et al (2019) RET fusions in solid tumors. Cancer Treat Rev 81:101911","journal-title":"Cancer Treat Rev"},{"key":"1593_CR4","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","volume":"30","author":"R Wang","year":"2012","unstructured":"Wang R, Hu H, Pan Y et al (2012) RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 30:4352\u20134359","journal-title":"J Clin Oncol"},{"key":"1593_CR5","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/j.jtho.2018.07.004","volume":"13","author":"A Drilon","year":"2018","unstructured":"Drilon A, Lin JJ, Filleron T et al (2018) Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET-rearranged lung cancers. J Thorac Oncol 13:1595\u20131601","journal-title":"J Thorac Oncol"},{"key":"1593_CR6","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","volume":"29","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Velcheti V, Touch BB et al (2018) Selective RET kinase inhibition for patints with RET-altered cancers. Ann Oncol 29:1869\u20131876","journal-title":"Ann Oncol"},{"key":"1593_CR7","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, Solomon B, Loong HH et al (2023) First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med 389:1839\u20131850","journal-title":"N Engl J Med"},{"key":"1593_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","volume":"383","author":"A Drilon","year":"2020","unstructured":"Drilon A, Oxnard GR, Tan DSW et al (2020) Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 383:813\u201324","journal-title":"N Engl J Med"},{"issue":"15","key":"1593_CR9","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1200\/JCO-24-02076","volume":"43","author":"G Oliver","year":"2025","unstructured":"Oliver G, Keunchil P, Benjamin JS et al (2025) Selpercatinib in RET fusion-positive non-small cell lung cancer: final safety and efficacy, including overall survival, from the LIBRETTO-001 phase\u2160\/\u2161 trial. J Clin Oncol 43(15):1758\u20131764","journal-title":"J Clin Oncol"},{"key":"1593_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356145","volume":"6","author":"Z-Y Dong","year":"2017","unstructured":"Dong Z-Y, Zhang J-T, Liu S-Y, Su J, Zhang C, Xie Z, Zhou Q, Tu H-Y, Xu C-R, Yan L-X et al (2017) EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology 6:e1356145","journal-title":"Oncoimmunology"},{"key":"1593_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","volume":"31","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Rizvi H, Bandlamudi C et al (2020) Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol 31:599\u2013608","journal-title":"Ann Oncol"},{"key":"1593_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2019.10.019","volume":"124","author":"CY Yang","year":"2020","unstructured":"Yang CY, Liao WY, Ho CC et al (2020) Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur J Cancer 124:110\u2013122","journal-title":"Eur J Cancer"},{"issue":"5","key":"1593_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jtho.2023.01.008","volume":"18","author":"YR Murciano-Goroff","year":"2023","unstructured":"Murciano-Goroff YR, Falcon CJ, Lin ST et al (2023) Central nervous system disease in patients with RET fusion-positive NSCLC treated with selpercatinib. J Thorac Oncol 18(5):620\u2013627","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1593_CR14","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1186\/s12885-024-13250-1","volume":"24","author":"J Qian","year":"2024","unstructured":"Qian J, Zhang S, Jiang C et al (2024) Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database. BMC Cancer 24(1):1486","journal-title":"BMC Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01593-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01593-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01593-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T04:25:18Z","timestamp":1767068718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01593-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1593"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01593-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests:  Yasuhiro Mihashi received honoraria from Chugai and Boehringer Ingelheim. Akihiro Tsukaguchi received honoraria from AstraZeneca, Chugai, and MSD. Satoshi Tanaka received honoraria from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Chugai, Kyorin, MSD, Taiho, and Takeda. Naoko Katsurada received honoraria from Bristol-Myers Squibb, Chugai, MSD, AstraZenec, Taih, and Eisai. Takeshi Nakatani received honoraria from AstraZeneca, Sanofi, GlaxoSmithKline, Boehringer Ingelheim, Chugai, Daiici-Sankyo, MSD, Nippon-kayaku, and Bristol Myers Squibb. Yuki Takeyasu received honoraria from AstraZeneca, Chugai, Daiici-Sankyo, Eli Lilly, MSD, Nipppon-kayaku, Novartis, Ono, Bristol Myers Squibb, Phizer, Taiho, Zeria, and Takeda. Taiichiro Otsuki received honoraria from AstraZeneca, Chugai, Daiici-Sankyo, Eisai, Kyowa-kirin, MSD, Nippon-kayaku, Ono, Taiho, and Takeda. Satoshi Tetsumoto received honoraria from AstraZeneca, Chugai, Kyowa-kirin, Nippon-kayaku, and GlaxoSmithKline. Akihiro Tamiya received honoraria from Eli Lilly, Ono, Chuga, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb, Amgen, Taiho, Kyowa Kirin, MSD, Takeda, Nippon-Kayaku, Novartis, Thermo Fischer, Tsumura, Daiich-Sankyo, Pulmonx, and Merck BioFarma, and research funding from Daiichi-Sankyo, Beigene, Taiho Pharmaceutical and AstraZeneca. Takayuki Shiroyama received honoraria from Chugai, Eli Lilly, Ono, AstraZeneca, and MSD. Motoko Tachihara received honoraria from Eli Lilly, Chugai, AstraZeneca, MSD, Taiho, Boehringer Ingelheim, Ono, Bristol-Myers Squibb, Nippon-Kayaku, Takeda, Pfizer, Daiichi Sankyo, Novartis, Pfizer, Janssen, Merck Biopharma and research funding from AstraZeneca, Chugai. Kazumi Nishino received honoraria from Amgen, Astrazeneca, Boehringer Ingelheim, Bristol-Myers-Squibb, Chugai, Daiici-Sankyo, Eli Lilly, Merck, MSD, Nipppon-kayaku, Novartis, Ono, Phizer, and Takeda, and research funding from Amgen, Astrazeneca, Boehringer Ingelheim, Bristol-Myers-Squibb, Chugai, Daiici-Sankyo, Eli Lilly, Janssen, Merck, MSD, Nihon-kayaku, Novartis, Ono, Phizer, and Takeda. Takayasu Kurata received honoraria from AstraZeneca, Chugai, Eli Lilly, Amgen, Janssen, MSD, Nippon-Kayaku, Novartis, Ono, Bristol Myers, Pfizer, Taiho, Asahi Kasei, Merck, Eisai, and Takeda and research funding from MSD, Chugai, Daiichi-Sankyo, Delta-Fly, Amgen, Taiho, Janssen, and Regeneron. Masahide Mori received honoraria from AbbVie, AstraZeneca, Boehringer Ingelheim, Chugai, Daiici-Sankyo, Eli Lilly, Kyowa-kirin, MSD, Nihon-kayaku, Novartis, Ono, Phizer, Taiho, and Takeda and research funding from Chugai, Daiichi-Sankyo, Delta-Fly, Janssen, Ono, and Samsung.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}